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Summary
Germline mutations in LKB1, TSC2, or PTEN tumor suppressor genes result in hamartomatous syndromes with shared
tumor biological features. The recent observations of LKB1-mediated activation of AMP-activated protein kinase (AMPK)
and AMPK inhibition of mTOR through TSC2 prompted us to examine the biochemical and biological relationship between
LKB1 and mTOR regulation. Here, we report that LKB1 is required for repression of mTOR under low ATP conditions in
cultured cells in an AMPK- and TSC2-dependent manner, and that Lkb1 null MEFs and the hamartomatous gastrointestinal
polyps from Lkb1 mutant mice show elevated signaling downstream of mTOR. These findings position aberrant mTOR
activation at the nexus of these germline neoplastic conditions and suggest the use of mTOR inhibitors in the treatment
of Peutz-Jeghers syndrome.
Introduction (reviewed in Manning and Cantley, 2003). The PTEN tumor sup-
pressor encodes a lipid phosphatase that serves to dephos-
The LKB1 tumor suppressor is a serine/threonine kinase that phorylate the D3 position of phosphatidylinositol-3,4,5-tris-
is mutationally inactivated in the autosomal dominant Peutz- phosphate and thus biochemically directly opposes the activity
Jeghers syndrome (Boudeau et al., 2003), as well as in some of phosphoinositide 3-kinase (PI 3-kinase) and its downstream
sporadic lung adenocarcinomas (Sanchez-Cespedes et al., effectors. Key among downstream PI3-kinase effectors is the
2002; Carretero et al., 2004). In the mouse, Lkb1 nullizygosity Akt serine/threonine kinase, which mediates cell proliferation,
is embryonic lethal (circa E9–E11) due to vascular and neural survival, and growth. Inactivating mutations in PTEN in the con-
tube defects (Ylikorkala et al., 2001), and Lkb1 heterozygosity text of inherited syndromes, or in sporadic tumors, such as
engenders sporadic hamartomatous gastrointestinal polyps those of the prostate, breast, and glia, thus cause elevated Akt
which phenocopy those of PJS patients (Bardeesy et al., 2002;
activity (Cantley and Neel, 1999). Akt activates mTOR signaling
Miyoshi et al., 2002; Jishage et al., 2002; Rossi et al., 2002).
by directly phosphorylating and inactivating the TSC2 tumorHamartomas are benign tumors consisting of normal cellular
suppressor tuberin (Manning et al., 2002; Inoki et al., 2002).differentiation but disorganized tissue architecture, and are
Furthermore, tuberin is constitutively phosphorylated at thepresent in several inherited tumor syndromes, including Cow-
same sites in cells derived from tumors lacking PTEN (Manningden’s disease/Bannayan-Zonana syndrome and tuberous scle-
et al., 2002). Activation of the mTOR pathway has been pre-rosis complex, which possess germline-inactivating mutations
viously documented in Tsc2- and Pten-deficient tissues andin the tumor suppressors PTEN and either TSC1 or TSC2, re-
tumors in vivo (Kwiatkowski et al., 2002; Zhang et al., 2003;spectively.
Stambolic et al., 1998; Ramaswamy et al., 1999; Sun et al.,TSC1 and TSC2 gene products—hamartin and tuberin, re-
1999). Moreover, aberrant cell growth in these systems is spe-spectively—are components of a complex that negatively regu-
cifically suppressed by treatment with mTOR inhibitors, suchlates mTOR signaling and, correspondingly, inactivation of
TSC1 or TSC2 is associated with elevated mTOR activity as rapamycin (Neshat et al., 2001; Podsypanina et al., 2001;
S I G N I F I C A N C E
LKB1 mutations are associated with the Peutz-Jeghers syndrome (PJS), consisting of pigmentation anomalies, benign gastrointestinal
polyps (hamartomas), and predisposition to a range of malignant tumor types. This study forges a biochemical and genetic link
from Lkb1 to mTOR signaling via the sequential activation of AMPK and the TSC2 tumor suppressor. This interrelationship, particularly
hyperactive mTOR signaling, provides a rational explanation for the shared features of three human disorders characterized by the
development of hamartomas (PJS, Cowden’s disease, and tuberous sclerosis complex). mTOR inhibitors, including rapamycin analogs,
which are currently under clinical trials for a number of cancers, may be effective in the treatment and possible prevention of Peutz-
Jeghers polyps and sporadic tumors that show LKB1 loss.
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Shi et al., 2002; Kenerson et al., 2002; Jaeschke et al., 2002; activate 11 other AMPK-related kinases, similarly through direct
phosphorylation of their activation loop threonines (Lizcano etOnda et al., 2002; Kwon et al., 2003).
mTOR is a highly conserved serine/threonine kinase that al., 2004). The kinase activity of LKB1 or any of the AMPK-
related kinases is not directly regulated by AMP (Hawley et al.,regulates protein synthesis and cell growth in all eukaryotes
(Shamji et al., 2003; Harris and Lawrence, 2003). Two well- 2003; Shaw et al., 2004; Lizcano et al., 2004; Sakamoto et
al., 2004). These data raise the possibility that, among LKB1-characterized targets of mTOR signaling are S6K1 and 4E-BP1
(Fingar and Blenis, 2004). S6K1 is activated downstream of regulated kinases, the 1 and  2 AMPK subunits are uniquely
responsive to energy stress, probably reflecting a unique abilitymTOR and insulin signaling by multisite phosphorylation, which
stimulates its kinase activity toward downstream substrates, to associate with the AMP binding  subunits. Whether the
activities of the AMPK-related kinases are regulated in responsesuch as the ribosomal protein S6. mTOR has been shown to
be necessary for the phosphorylation of Thr389 in human S6K1. to other stimuli is not known, however, in LKB1-expressing cells,
several of these kinases appear to be constitutively activated.S6K1 is a critical modulator of cell growth in mammalian cells,
although the mechanism by which this is mediated is currently Given that LKB1 serves to activate AMPK, and AMPK serves
to negatively regulate mTOR in some contexts, we sought tounknown. 4E-BP1 is similarly regulated by multisite phosphory-
lation downstream of mitogen-stimulated mTOR. When hypo- determine whether mTOR signaling was aberrantly elevated in
Lkb1 deficient cells as well as in gastrointestinal polyps derivedphosphorylated, 4E-BP1 acts as a repressor of cap-dependent
translation by binding to eIF4E and preventing proper formation from Lkb1 mutant mice. Additionally, we sought to determine
whether LKB1 and TSC2-deficient cells shared other biochemi-of the eIF4F translation initiation complex at the 5 end of
mRNAs. Following growth factor stimulation, 4E-BP1 is sequen- cal and physiological properties.
tially phosphorylated on a number of sites, causing its dissocia-
tion from eIF4E, thereby promoting cap-dependent translation. Results
mTOR signaling is inhibited under conditions of low nutri-
ents, such as glucose and amino acids and low intracellular To examine the role of AMPK in the regulation of mTOR signaling
under physiological conditions, we evaluated mTOR activity inATP levels (Shamji et al., 2003). While mTOR was presumed to
serve as the direct cellular sensor for ATP levels (Dennis et al., wild-type and Lkb1-deficient mouse embryonic fibroblasts
(MEFs). In normal growth media, Lkb1/ and / MEFs show2001), mounting evidence has implicated AMP-activated protein
kinase (AMPK), a well-characterized sensor of intracellular ATP/ low AMPK activity, as evidenced by lack of phosphorylation of
the critical AMPK effector acetyl CoA carboxylase (ACC) (FigureAMP ratios, in the regulation of mTOR activity (Kimura et al.,
2003). Specifically, enforced expression of activated AMPK in 1A). Under these conditions, phosphorylation of S6K1 and its
substrate ribosomal S6 were readily detectable, consistent withcells not undergoing energy stress showed inhibition of mTOR
signaling, whereas kinase-dead AMPK dominantly inhibited high levels of mTOR activity. On the other hand, in response to
treatment with 5-aminoimidizole-4-carboxamide ribosidemTOR signaling in the setting of energy stress (Kimura et al.,
2003). The precise target of AMPK that regulates mTOR signal- (AICAR), which serves as a cell permeable AMP mimetic (Hardie
et al., 2003), AMPK is activated and S6K1 is inhibited in wild-ing has recently come to light in studies establishing that AMPK
directly phosphorylates and enhances the ability of tuberin to type cells. Strikingly, in the Lkb1-deficient fibroblasts, AMPK
activation by AICAR is severely attenuated, and levels of activeinhibit mTOR signaling (Inoki et al., 2003). Indeed, cells lacking
TSC2 are unable to downregulate mTOR following energy S6K1 remain high (Figure 1A). In contrast, growth factor signal-
ing to GSK-3, reflective of Akt activity in these cells, is unaffectedstress. However, to date, the role of AMPK in the regulation of
mTOR has yet to be validated by genetic means. by AICAR-induced energy stress. We obtained similar results
following treatment with the AMPK agonist phenformin (dataThe LKB1 tumor suppressor gene encodes a serine/threo-
nine kinase shown recently to be the major upstream kinase of not shown). To ensure that sustained elevation of mTOR activity
was not a secondary consequence of LKB1 deficiency, we sta-AMPK (Hawley et al., 2003; Woods et al., 2003; Shaw et al.,
2004). LKB1 directly phosphorylates Thr172 in the activation bly reconstituted immortalized Lkb1/ MEFs with retroviruses
encoding wild-type or kinase-dead Lkb1. As seen in Figure 1B,loop of AMPK, a modification that is absolutely required for
AMPK catalytic activity (Stein et al., 2000). AMPK exists as a wild-type but not kinase-dead Lkb1 restored the sensitivity of
S6K1 activity to energy stress. A modest, but reproducible,heterotrimer in cells, composed of a catalytic kinase subunit ()
and two regulatory subunits ( and ) (Hardie et al., 2003). The effect on S6 phosphorylation was also seen under unstimulated
conditions in wild-type Lkb1-reconstituted cells (Figure 1B, subunit contains a series of CBS domains that bind AMP (Scott
et al., 2004) and, once bound to AMP, induces a conformation lane 2).
To address whether other known effectors of mTOR werechange in the AMPK heterotrimer which allows it to serve as a
better substrate for upstream activating kinases such as LKB1 similarly deregulated by Lkb1 loss, or if S6K1 was specifically
affected, we examined the regulation of 4E-BP1. The mTOR-(Kemp et al., 2003). In mammalian cells, there are two catalytic
 subunits with some distinct and some overlapping functions, dependent phosphorylation of 4E-BP1 is known to inhibit its
association with eIF4E and the 5-cap complex. The compo-as evidenced by germline inactivation of each gene in the mouse
(Viollet et al., 2003; Jorgensen et al., 2004), although mice and nents of endogenous cap complexes can be assayed using
7-methyl GTP sepharose as an affinity reagent (Fingar et al.,cells doubly deficient for both subunit genes, and hence genet-
ically devoid of AMPK activity, have yet to be reported. The 2002). As seen in Figure 1C (left panel), 4E-BP1 exists as a
number of species with different mobilities on SDS-PAGE duepresence of 2  subunit genes and 3  subunit genes has
similarly precluded a definitive genetic assessment of AMPK to differences in phosphorylation, with the slowest mobility form
being the hyper-phosphorylated form. In growing cells, 4E-BP1deficiency in mammalian cells.
In addition to the two AMPKs, LKB1 has been shown to is hyperphosphorylated and very little copurifies in cap com-
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Figure 1. mTOR signaling is not inhibited following
energy stress in LKB1-deficient cells
A: Subconfluent cycling littermate-matched pri-
mary MEFs of the indicated genotype were left
untreated (NT) or were treated with 2 mM AICAR
for 2 hr. Total cell extracts were immunoblotted
for phospho-Thr172 AMPK (P-AMPK), phosphor-
Ser79 ACC (P-ACC), phospho-Thr389 S6K1
(P-S6K1), phospho-Ser9 GSK-3b (P-GSK-3), and
phospho-Ser235/236 S6 ribosomal protein (P-S6).
B: An immortalized LKB1/ MEF cell line was re-
constituted with vector (v), wild-type (wt), or ki-
nase-dead (kd) human LKB1-expressing retrovi-
ruses. Cells were treated as in A. eIF4E was used
as a loading control. * represents a crossreactive
band with the anti-LKB1 antisera as character-
ized previously (Shaw et al., 2004).
C: Endogenous 5 cap complexes were isolated
from LKB1 primary MEFs as in A. 10% of the total
cell lysate is shown in the left panels; cap com-
plexes purified on 7-methyl sepharose are shown
in right panels. Each was immunoblotted with
total 4E-BP1 and eIF4E antibodies. eIF4E is shown
as a loading control.
D: HeLa cells (which are LKB1-deficient) were
transiently transfected with vector, FLAG-tagged
wild-type, or kinase-dead LKB1 along with an HA-
tagged S6K1 or an HA-tagged 4E-BP1 construct,
then treated where indicated with 2 mM AICAR for 2 hr. S6K1 immunoprecipitates were immunoblotted for activating phosphorylation of S6K1 as before,
as well as with anti-HA to control for levels. Lysates were immunoblotted with anti-FLAG to detect levels of LKB1 and with anti-HA to detect phosphorylation-
induced changes in 4E-BP1 mobility on SDS-PAGE.
plexes, and that which does is restricted to the hypophosphory- phorylate tuberin. As seen in Figure 2A, AMPK activated by wild-
type LKB1 directly phosphorylates tuberin in vitro. Moreover, welated forms. Notably, treatment of wild-type MEFs with AICAR
significantly increases the level of the hypophosphorylated 4E- noticed that when tuberin was stoichiometrically phosphory-
lated by AMPK, it underwent a mobility shift when resolved onBP1 and concomitantly leads to increased 4E-BP1 association
with the cap complex. Interestingly, Lkb1-deficient cells dis- low percentage SDS-PAGE gels (Figure 2B). This mobility shift
in tuberin was not observed when tuberin was phosphorylatedplayed less 4E-BP1 associated with the cap complex, both
under basal conditions and, more markedly, following AICAR by active recombinant Akt, even at levels of tuberin phosphory-
lation comparable to those induced by AMPK (B.D.M., unpub-treatment (Figure 1C). This is also reflected in the near absence
of hypophosphorylated 4E-BP1 following AICAR treatment in lished data). To assess this phosphorylation in vivo, we cotrans-
fected HeLa cells with FLAG-tagged tuberin with or withoutthe total cell lysates (Figure 1C, top left panel).
To determine whether LKB1 deficiency impacts broadly on LKB1. We then examined the mobility of tuberin on SDS-PAGE
following treatment with AICAR. HeLa cells expressing wild-mTOR signaling, we tested the LBK1-mTOR link in a distinct
cell type of human origin—HeLa cells were selected as they are type LKB1 induced a significant reduction in tuberin mobility
after treatment of the cells with AICAR (Figure 2C), suggestingknown to lack LKB1 expression (Tiainen et al., 1999). Following
transduction of wild-type or kinase-dead LKB1 along with HA- LKB1-induced AMPK activation and subsequent phosphoryla-
tion of tuberin. AICAR treatment in the absence of LKB1 expres-tagged S6K1 or 4E-BP1 constructs, we assayed mTOR activa-
tion of S6K1 by immunoblotting HA immunoprecipitates with sion had no effect on tuberin mobility in HeLa cells (data not
shown).anti-phosphoT389 antisera and mTOR phosphorylation of 4E-
BP1 by mobility shift on SDS-PAGE. As seen in Figure 1D, In order to more rigorously examine the requirement of
AMPK for LKB1-mediated inhibition of mTOR signaling, we in-introduction of wild-type, but not kinase-dead, LKB1 into HeLa
cells restores AICAR-dependent inhibition of S6K1 and 4E-BP1 troduced wild-type LKB1 into HeLa cells with or without two
different dominant-negative AMPK constructs—a kinase-deadphosphorylation in response to energy stress, indicating that
LKB1-dependent mTOR regulation is conserved in humans and 2 allele and a nonactivatible T172A 1 allele (Crute et al., 1998).
As seen in Figure 2D, coexpression of either dominant-negativein different cell types.
Recent studies have demonstrated that the TSC2 tumor AMPK  allele blocked the ability of LKB1 to downregulate S6K1
in AICAR-treated HeLa cells.suppressor protein, tuberin, is a direct target of AMPK and a
critical mediator of AMPK-dependent inhibition of mTOR signal- We next wished to determine whether other known stresses
that inhibit mTOR activity might also function through LKB1/ing (Inoki et al., 2003). We sought to examine whether LKB1
can regulate tuberin phosphorylation via AMPK, and whether AMPK. For these experiments, we compared the response of
littermate-matched Lkb1/ and / MEFs to littermate-matchedAMPK itself is critical for the effects of LKB1 in downregulating
mTOR signaling. First, we examined the ability of purified recom- p53-deficient Tsc2/ and / MEFs. Tsc2/ MEFs have been
reported to display aberrantly high levels of mTOR signaling inbinant AMPK preactivated in vitro with LKB1 to directly phos-
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contrast, in Tsc2/cells, S6K1 is not inhibited in response to
any of these stimuli (Figures 3A and 3B). Importantly, rapamycin
inhibited S6K1 activity in all cell types. In order to examine
whether other mitogenic signaling pathways are affected by
the loss of Lkb1, we used phospho-specific antibodies that
recognize activated forms of Erk and Akt. We found that neither
Erk nor Akt activation was enhanced in Lkb1-deficient cells
following any of the aforementioned cellular stresses. In fact,
Akt activation was reduced in LKB1-deficient cells as compared
to wild-type controls under several conditions, including serum
deprivation, serum stimulation, and AICAR treatment (Figure 3).
Similarly, as seen previously (Kwiatkowski et al., 2002; Jaeschke
et al., 2002), Akt activity is dramatically attenuated in the Tsc2-
deficient cells following all stimuli, a phenomenon which has
previously been attributed to a negative feedback loop inhibiting
PI3K/Akt signaling in a number of systems (Garami et al., 2003).
Given these similarities in intracellular signaling, we exam-
ined whether Lkb1/ MEFs might share any biological proper-
ties with TSC2/ MEFs. One property of LKB1-deficient cells
that we previously characterized was their sensitivity, relative
to wild-type cells, to undergo apoptosis following treatment with
AICAR or other AMPK agonists (Shaw et al., 2004). Notably,
Tsc2/ MEFs were recently found to undergo apoptosis under
conditions of glucose deprivation, which also serves to activate
AMPK (Inoki et al., 2003). Interestingly, this property of Tsc2-
deficient MEFs was rescued by concurrent treatment with rapa-
mycin. We therefore investigated whether glucose deprivation
would also selectively lead to the apoptosis of Lkb1-deficient
MEFs and whether this effect could be rescued by rapamycin
treatment. First, we characterized that AMPK signaling and
mTOR was aberrant in LKB1/ cells following glucose depriva-
Figure 2. LKB1 activation of AMPK stimulates phosphorylation of tuberin tion, as seen in Figure 3C. As expected, in the LKB1/ cells,
in vitro and in vivo and is required for LKB1-mediated inhibition of S6K1 phospho-S6 was elevated and phospho-ACC was decreased,
activity
indicating a defect in AMPK signaling in these cells following
A: In vitro kinase assay using FLAG-tagged tuberin as a substrate for LKB1- glucose deprivation. Using caspase activation—as detected by
activated AMPK. Purified E. coli-produced recombinant AMPK was acti-
PARP cleavage in lysates—as a measure of apoptosis (Shawvated by an in vitro kinase assay with wild-type LKB1, kinase-dead LKB1, or
et al., 2004; Inoki et al., 2003), we observed that Lkb1/ MEFsuntransfected control immunoprecipitates, then isolated and assayed for
its ability to phosphorylate tuberin in vitro. show elevated sensitivity to apoptosis induced by glucose with-
B: Comparison of recombinant Akt-mediated tuberin phosphorylation drawal as compared to their wild-type counterparts, and that
in vitro to recombinant AMPK phosphorylation in vitro. Note that only AMPK-
rapamycin potently inhibited this apoptotic phenotype (Figuremediated phosphorylation induces a significant mobility shift in tuberin on
3C). The PARP cleavage in lysates was mirrored in direct assaysSDS-PAGE.
C: HeLa cells were cotransfected with FLAG-tagged tuberin and either of cell viability (Figure 3D). These results confirm the sensitivity
empty vector or wild-type LKB1 and treated with 2 mM AICAR where indi- of LKB1/ MEFs to glucose deprivation-induced cell death and
cated. Total cell lysates were then immunoblotted with anti-FLAG antisera the suppression of this effect by rapamycin.
to detect the introduced tuberin. Note the significant mobility shift induced
The regulation of mTOR by LKB1 in vivo is intriguing in lightby AICAR treatment of LKB1-expressing cells. AICAR treatment of cells not
of the established role of mTOR activation in the pathogenesisexpressing wild-type LKB1 had no effect on tuberin mobility (data not
shown). of human tumors. We wished to begin to address the potential
D: HeLa cells were transfected with HA-tagged S6K1 and FLAG-tagged role of mTOR deregulation in the pathogenesis of the hamarto-
wild-type LKB1 along with empty vector, or dominant negative AMPK 1
matous polyps that characterize LKB1-deficiency in both hu-(GST-tagged) or dominant negative AMPK 2 (myc tagged). Cells were
mans and mice. We therefore investigated the status of thetreated with 2 mM AICAR for 2 hr where indicated. HA immunoprecipitates
were immunoblotted with phospho-Thr389 S6K1 antisera to detect acti- mTOR pathway in hamartomatous gastrointestinal polyps aris-
vated S6K1 and reprobed for total HA-S6K1 levels. Lysates were immunoblot- ing in Lkb1/ mice. Western blot analyses of lysates from pol-
ted with anti-FLAG to detect LKB1 levels and with anti-myc and anti-GST to yps and adjacent gastrointestinal epithelium revealed a promi-detect expression of the dominant negative AMPK alleles.
nent elevation in phospho-S6 and phospho-S6K1 (Thr389)
levels in all polyps analyzed (Figure 4A). Furthermore, we de-
tected elevated levels of phospho-4E-BP1 (Ser65), indicating
that mTOR-dependent signaling is elevated in the polyps. Thisresponse to a wide variety of cellular stresses (Zhang et al.,
property appears to be specific to Lkb1 deficiency rather than2003). As seen in Figure 3A, Lkb1/ cells fail to downregulate
secondary to the deregulated growth state of the polyps, sinceS6K1 activity following AICAR treatment, as shown above. How-
other growth-associated markers, such as phospho-Erk (Figureever, LKB1-deficient cells quite effectively downregulate S6K1
activity following amino acid and growth factor deprivation. In 4A) and phospho-Akt levels (data not shown), did not show
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Figure 3. LKB1- and TSC2-deficient MEFs show
similar aberrant deregulation of intracellular sig-
naling in response to specific environmental
stresses
A and B: Littermate-matched LKB1- or TSC2-
deficient MEFs were compared to wild-type MEFs
in their response to a number of stress stimuli
known to inhibit mTOR signaling (wild-type cells
denoted , / cells simply ). mTOR signaling
was examined by immunoblotting for phospho-
S6 as in Figure 1. Activation of Akt and Erk were
examined using their specific activation state
phospho-specific antibodies (Ser473 for Akt,
Thr202/Tyr204 for Erk). As before, eIF4E is used as
a loading control. All MEFs were serum-deprived
in DMEM alone for 24 hr. Indicated samples were
then placed in fresh media containing 10% se-
rum, with or without 20 nm rapamycin or 2 mM
AICAR, all for 90 min. Amino acid deprivation
(AA) was performed by placing the serum-
starved cells into D-PBS with 10% dialyzed serum
for 90 min.
C: LKB1-deficient MEFs are hypersensitive to apo-
ptosis induced by glucose deprivation, and ra-
pamycin rescues this apoptosis. LKB1-deficient
MEFs exhibit defective AMPK activation and mTOR inhibiton following glucose deprivation. Prolonged treatment in glucose-free media leads apoptosis,
as indicated by the extent of caspase-mediated PARP cleavage in total cell lysates. Cells were placed in normal media, glucose-free media with 10%
dialyzed serum, or glucose-free media with 10% dialyzed serum containing 20 nM rapamycin for 6 or 24 hr as indicated. LKB1 genotype indicated at
bottom. eIF4E is used as a loading control.
D: Cells were treated for 24 hr as in C, and viability was quantified by MTT assays performed in triplicate on cells of the indicated genotypes. Cell death is
expressed as a percentage of the untreated controls.
consistent differences between polyp and adjacent normal tis- mTOR signaling is mediated through LKB1-dependent phos-
phorylation of AMPK in response to energy stress, and thatsue. These results were extended by immunohistochemical
analyses. While both the normal gastrointestinal epithelium ad- phosphorylation of tuberin by AMPK is a likely mechanism to
jacent to the polyp tissue and the polyp stroma showed minimal explain the effects on mTOR signaling. These results provide
immunoreactivity to anti-phospho-S6 antisera, the polyp epithe- strong biochemical and genetic evidence that endogenous
lium showed intense cytoplasmic staining (Figures 4B–4D). The AMPK mediates mTOR inhibition in response to decreased in-
activation of S6K1 in the polyps was further confirmed and tracellular ATP.
extended by additional immunohistochemical studies that re- Consistent with mTOR as a key effector in the biology of
vealed strong staining for phospho-S6K1 (Thr421/Ser424) spe- LKB1, Tsc2/ and Lkb1/ MEFs share a number of properties
cifically in the polyp epithelium (Figure 4E). The staining pattern that are uncharacteristic of cells lacking most tumor suppres-
showed both nuclear and cytoplasmic localization consistent sors. Both cell types are hypersensitive to apoptosis induced
with increased phosphorylation of both the p70 and p85 S6K by energy stress, and this adverse response can be rescued
isoforms. Importantly, the epithelial cells within the polyp that by treatment with the mTOR inhibitor rapamycin. Both also
contain elevated levels of phospho-S6 and -S6K1 are thought display attenuated Akt activation under most conditions, which
to be the neoplastic component of the polyp (Hemminki et al., is in stark contrast to loss of Pten, which causes hyperactivation
1997; Wang et al., 1999, Entius et al., 2001; Bardeesy et al., of Akt. Finally, immortalized MEFs deficient for either TSC2 or
2002). LKB1 proliferate more slowly than their wild-type littermate-
derived counterparts (R.J.S, N.B., and B.D.M., unpublished
data). Aberrant mTOR signaling might also explain two majorDiscussion
molecular markers of LKB1 loss previously characterized. VEGF
has been shown to be upregulated in embryos and MEFs defi-The development of hamartomas is a stereotypical feature of a
number of clinically related human tumor disorders, including cient for LKB1 (Ylikorkala et al., 2001; Bardeesy et al., 2002) or
TSC2 (El-Hashemite et al., 2003; Brugarolas et al., 2003). OfPeutz-Jeghers syndrome, Cowden’s disease (and related Pten-
deficiency disorders), and tuberous sclerosis complex (Gomez note, the increase in VEGF protein levels in LKB1-deficient MEFs
is not associated with increased VEGF mRNA levels (Bardeesyet al., 1999; Cantley and Neel, 1999; Devroede et al., 1988). As
previously demonstrated for Pten- and Tsc2-deficient tumors et al., 2002), a finding consistent with data demonstrating VEGF
to be one of several genes whose oncogene-induced recruit-in vivo, LKB1-deficient tumors are shown here to exhibit ele-
vated levels of S6K1 activity and phospho-4EBP1, indicative of ment of mRNA to polyribosomes is critically governed by mTOR
signaling (Rajasekhar et al., 2003). Another marker of LKB1hyperactivation of mTOR signaling, establishing hyperactivate
mTOR signaling as a common theme across these distinct tumor loss is the expression of IGFBP5, the single most upregulated
transcript in LKB1/ mouse GI polyps as compared to normalsuppressor disorders (Figure 5). In this study, we further demon-
strate that, in cell culture-based systems, LKB1 modulation of surrounding tissue. IGFBP5 mRNA levels are also aberrantly
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Figure 5. Model describing upstream regulation of mTOR signaling by tumor
suppressors mutated in hamartoma syndromes
In response to peptide growth factors and mitogenic stimuli, PI 3-kinase is
activated, resulting in the activation of the Akt serine/threonine kinase. Akt
directly phosphorylates and inactivates the TSC2 tumor suppressor protein
tuberin. Tuberin serves as a GTPase-activating protein (GAP) for the small
Ras-like GTPase Rheb. When tuberin is inactivated by Akt, Rheb-GTP levels
increase, leading to increased mTOR activity via an unknown mechanism.
The Pten tumor suppressor serves to biochemically antagonize PI-3 kinase
activity; hence, in Pten-deficient cells, Akt activity and mTOR activity are
high. In response to energy stress, cells activate AMPK downstream of the
LKB1 tumor suppressor. AMPK directly phosphorylates and activates tuberin,
overriding the mitogenic signal from Akt. In the absence of LKB1, AMPK
cannot be activated, nor can mTOR be inactivated, via tuberin, in response
to energy stress.
The multiple overlapping clinical features between Peutz-
Jeghers syndrome and Cowden’s disease (CD) caused us toFigure 4. S6K1 activity is dramatically increased in GI polyps from LKB1/
originally hypothesize that LKB1, like PTEN, might negativelymice as compared to surrounding normal tissue
regulate PI3-kinase signaling (Cantley and Neel, 1999). How-A: Lysates were made from polyps or adjacent normal tissue and subjected
ever, we have observed in a number of biological settings thatto immunoblotting with anti-phospho-S6, phospho-Erk, phospho-S6K1
(Thr389), phospho-4E-BP1 (Ser65), or total S6 as a loading control. AICAR- Akt activity is not increased in LKB1-deficient cells, and, if any-
treated LKB1 MEFs of the indicated genotype are in the rightmost two lanes thing, is decreased (see Figure 3A). This reduced Akt activation
as a comparison (analogous to those in Figure 1A).
in the LKB1-deficient cells can also account for the previousB: Hematoxylin and eosin (H&E)-stained section shows a polyp (upper) aris-
observation of decreased phospho-GSK3 (Ser9) in LKB1-defi-ing at the pyloric/duodenal junction and the adjacent normal duodenal
tissue (lower). The glandular structures of polyp epithelium (pe, arrows) are cient MEFs (Ossipova et al., 2003). These results suggest that
embedded in the polyp stroma. The normal epithelium of the duodenum the common biochemical basis underlying the PJS and CD
(ne) and the submucosa (sm) are indicated. syndromes is not due to a shared activation of PI3K/Akt signal-
C: Immunohistochemistry of a section adjacent to the tissue shown in B
ing but rather to upregulation of mTOR signaling in both LKB1-using anti-phospho-S6 antisera shows strong staining in the polyp epithelium
and Pten-deficient cells.and weak or absent staining in the polyp stroma and the normal duodenal
tissue. One significant question that remains is whether AMPK is
D: Higher-power view of the image shown in C demonstrates cytoplasmic the only kinase downstream of LKB1 that can downregulate
localization phospho-S6 staining in the polyp epithelium. The scattered im-
mTOR via TSC2 phosphorylation or other mechanisms. LKB1munoreactive cells in the normal epithelium have a morphology suggestive
has been demonstrated to activate 11 AMPK-related kinasesof plasma cells.
E: Immunohistochemistry with anti-phospho-S6 kinase antisera shows ele- in an energy stress-independent manner (Lizcano et al., 2004;
vated cytoplasmic and nuclear staining in the polyp epithelium. Sakamoto et al., 2004). In different cellular contexts, these ki-
nases may phosphorylate TSC2 or other shared substrates with
AMPK. Indeed, we have observed that LKB1 can regulate basal
mTOR signaling under nonstressed conditions (e.g., Figure 1C).high in the LKB1-deficient MEFs (Bardeesy et al., 2002). The
Additional work will be needed to determine whether any of thetranscription of IGFBP5 has previously been shown to be criti-
other AMPK-related kinases can regulate TSC2/mTOR, and tocally dependent on mTOR signaling and is inhibited by rapa-
determine which kinase contributes to mTOR regulation in themycin (Duan et al., 1999). Furthermore, IGFBP5 translation is
pathogenesis of Peutz-Jeghers polyposis. Additionally, phos-also dependent on mTOR (Rajasekhar et al., 2003). Thus, hyper-
phorylation of TSC2 may not be the only way in which AMPK,activation of mTOR signaling in the LKB1-deficienct MEFs, pol-
or related kinases, negatively regulates mTOR. The recent reportyps, and embryos is likely to explain their previously noted
elevated levels of VEGF and IGFBP5. that AMPK can directly phosphorylate mTOR itself, and does
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from Santa Cruz. AICAR was obtained from Toronto Research Chemicalsso under conditions of energy stress, offers another possible
(Downsview, ON, Canada). Glucose-free media, D-PBS (containing 1 g/linhibitory signal (Cheng et al., 2004). Therefore, while the lack
D-glucose) and dialyzed serum was from Gibco/BRL. Rapamycin was fromof response to energy stress in TSC2-deficient cells argues that
Calbiochem. 7-methyl GTP sepharose was obtained from Amersham Phar-
tuberin is important, it may not be the only target of AMPK in macia. MBP-AMPK (1–172) fusion protein was a generous gift of Drs. L.
mTOR regulation. Witters and R. Hurley (Dartmouth Medical School, Hanover, NH). Active
recombinant Akt and AMPK used in Figure 2B were purchased from UpstateRecently, LKB1 has been demonstrated to be necessary
Biotech (Lake Placid, NY) Constructs used: Flag-wild-type LKB1. Flag-kinaseand sufficient for polarity of single intestinal epithelial cells (Baas
dead (K78I) LKB1 and Flag-tuberin were described previously (Shaw et al.,et al., 2004). LKB1 kinase activity was shown to be necessary
2004, Manning et al., 2002). HA-4E-BP1 and HA-S6K1 were kind gifts of J.for this effect, although which of its 13 downstream effector
Blenis (Harvard Medical School, Boston, MA). pEBG- AMPK 1 T172A was
kinases might play a role in this process has not been delineated. a kind gift of Dr. L. Witters (Dartmouth Medical School, Hanover, NH).
Moreover, LKB1 is the mammalian homolog of Par-4 in C. ele- pCDNA3-AMPK2 (K45R) kinase-dead was a kind gift of M. Birnbaum (Uni-
versity of Pennsylvania Medical School, Philadelphia, PA). Littermate-derivedgans, which was one of the original par mutants identified in a
LKB1/ and / MEFs were prepared as described previously (Bardeesyscreen for early embryonic polarity and partitioning defects
et al., 2002) TSC2/ p53/ and control p53/ littermate MEFs were ob-(Watts et al., 2000). The Drosophila ortholog of LKB1 is also
tained from Dr. D. Kwiatkowski as previously described (Zhang et al., 2003).essential for early embryonic polarity (Martin and St Johnston,
HeLa cells were obtained from ATCC.
2003), and some of its role in that process is likely due to its
activation of the Par-1 kinase homolog, which is one of the 11 Cell culture
kinases related to AMPK that have recently been demonstrated Cells were cultured and retrovirally infected as previously described (Shaw
et al., 2004). HeLa cells were transiently transfected using HeLaMonsterto be activated by LKB1 (Lizcano et al., 2004). Thus, LKB1
transfection reagent according to manufacturer’s suggestions (Mirus, Madi-uniquely regulates both central metabolism, through AMPK, and
son, WI). Cells were serum-starved in DMEM without serum 14 hr post-at least some aspects of cell polarity via Par-1 homologs. There-
transfection, then 8 hr later the media was replaced with fresh DMEM with
fore, disruption of LKB1 in the gastrointestinal epithelium would 10% FBS or DMEM with 10% FBS and 2 mM AICAR. For the MEF experi-
potentially simultaneously result in aberrant mTOR activation ments in Figure 1, cells were plated at 1  106 cells/10 cm dish, then the
and defects in cell polarity. Whether LKB1-mediated inhibition next day the media was replaced with fresh DMEM with 10% FBS or DMEM
with 10% FBS and 2 mM AICAR. For the MEF experiments in Figures 3Aof mTOR plays a role in the establishment of cell polarity remains
and 3B, 1  106 cells of each genotype were plated and the next day serum-to be determined. However, it has been demonstrated that in
starved for 24 hr. Cells were either lysed as such or their media replacedyeast, TOR signaling is critically involved in cell polarity (Loewith
with fresh DMEM with 10% FBS, DMEM with 10% FBS and 2 mM AICAR,et al., 2002; reviewed in Harris and Lawrence, 2003).
DMEM with 10% FBS and 20 nM rapamycin, or D-PBS with 10% dialyzed
Together, with the results shown here, it is now evident FBS for 90 min. For Figures 3C and 3D, cells were plated and the next day
that dysregulated activation of mTOR is a common biochemical placed in glucose-free DMEM with 10% dialyzed FBS, with or without 20 nM
feature of several autosomal dominant syndromes character- rapamycin. Cells were kept in glucose-free media with or without rapamycin
for 24 hr. For MTT assays, cells were plated in 12-well dishes in triplicateized by the occurrence of hamartomas. These results also sug-
for each condition. MTT assays were performed as previously describedgest that rapamycin and its analogs may be useful for the treat-
(Shaw et al., 2004).ment of polyps arising in PJS patients and possibly in the subset
of lung adenocarcinomas that lack LKB1. The fact that rapa- Biochemistry
mycin can promote survival of LKB1-deficient cells under condi- MEFs were lysed in boiling SDS-lysis buffer (10 mM Tris [pH 7.5], 100 mM
tions of energy stress, as previously reported for TSC-deficient NaCl, 1% SDS) after the indicated treatments. After trituration, lysates were
equilibrated for protein levels using the BCA method (Pierce) and resolvedcells, suggests that there may be certain cell types that are
on 6%–12% SDS-PAGE gels, depending on the experiment. Gels weresensitive to growth inhibition by rapamycin, while others may
transferred to PVDF and Western blotted according to the antibody manufac-be refractory. The biological response to mTOR inhibition via
turer’s suggestions. Immunoprecipitations, kinase assays, and 7-methyl GTPrapamycin (growth arrest versus apoptosis) is also known to
pulldowns were performed as previously described (Shaw et al., 2004, Man-
depend on other factors such as p53 status (Huang et al., 2003). ning et al., 2002, Fingar et al., 2002).
While rapamycin might allow LKB1-deficient cells to survive in
response to energy stress in vitro, it is unlikely that these cells Mice colony monitoring and tissue isolation
Lkb1/ mice, maintained on an FVB/N genetic background, were monitoredwould continue to proliferate in the presence of rapamycin.
for the development of gastrointestinal polyps as described (Bardeesy etOf course, additional studies will be required to validate these
al., 2002). Mice with clinical signs of disease were euthanized and autopsied.possibilities, but the similarity of the polyps developed in the
The mean latency, distribution of polyps, and polyp phenotype were compa-
LKB1 heterozygous mice to those in PJS patients suggests that rable to previous studies (Bardeesy et al., 2002). Polyps and adjacent tissue
these mice represent an ideal tool to examine this potential were harvested immediately and either processed for histological analysis
therapeutic regiment. or snap frozen in liquid nitrogen for molecular studies. These samples were
then placed frozen into Nunc tubes and homogenized in lysis buffer (20 mM
Experimental procedures Tris [pH 7.5], 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100,
2.5 mM pyrophosphate, 50 mM NaF, 5 mM -glycero-phosphate, 50 nM
Reagents and cell lines calyculin A, 1 mM Na3VO4, 10 mM PMSF, 4 g/ml leupeptin, 4 g/ml
Anti-phospho-AMPK (T172), anti-phospho-ACC (S79), anti-phospho-S6K1 pepstatin, 4 g/ml aprotinin) on ice for 30 sec using a tissue homogenizer.
(T389), anti-phospho-S6K1 (T421/S424), anti-phospho-GSK-3 (S9), anti-
phospho ribosomal protein S6 (S235/236), anti-ribosomal protein S6, anti- Histology and immunohistochemistry
eIF4E, anti-phospho-Akt (S473), anti-phospho-Erk (T202/Y204), anti-4E- Tissues were fixed in ice-cold 10% formalin overnight and embedded in
BP1, and cleaved PARP (mouse-specific) antibodies were obtained from Cell paraffin. For immunohistochemistry, slides were deparaffinized in xylene and
Signaling Technology (Beverly, MA). Anti-LKB1 antiserum was previously rehydrated sequentially in ethanol. Antigen retrieval using Antigen Un-
described (Bardeesy et al., 2002). Anti-Flag antibodies (M2 monoclonal and masking Solution (Vector) was performed according to the manufacturer’s
instructions. Slides were quenched in hydrogen peroxide (0.3%–3%) toFlag polyclonal) were from Sigma. Anti-HA probe polyclonal antibody was
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El-Hashemite, N., Walker, V., Zhang, H., and Kwiatkowski, D.J. (2003). Lossblock endogenous peroxidase activity and then washed in Automation Buffer
of Tsc1 or Tsc2 induces vascular endothelial growth factor production(Biomeda). Slides were blocked in 5% normal serum for 1 hr at room temper-
through mammalian target of rapamycin. Cancer Res. 63, 5173–5177.ature. Slides were incubated at 4	C overnight with primary antibody diluted
in blocking buffer. The avidin-biotin peroxidase complex method (Vector) Entius, M.M., Keller, J.J., Westerman, A.M., van Rees, B.P., van Velthuysen,
was used, and slides were counterstained with hematoxylin. Slides were M.L., de Goeij, A.F., Wilson, J.H., Giardiello, F.M., and Offerhaus, G.J. (2001).
dehydrated sequentially in ethanol, cleared with xylenes, and mounted with Molecular genetic alterations in hamartomatous polyps and carcinomas of
Permount (Fisher). The anti-phospho ribosomal protein S6 antibody (S235/ patients with Peutz-Jeghers syndrome. J. Clin. Pathol. 54, 126–131.
236) and anti-phospho-S6K1(T421/S424) were diluted according to manu-
Fingar, D.C., and Blenis, J. (2004). Target of rapamycin (TOR): An integratorfacturer’s suggestions (Cell Signaling Technology, Beverly, MA).
of nutrient and growth factor signals and coordinator of cell growth and cell
cycle progression. Oncogene 23, 3151–3171.Acknowledgments
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